Biosion is a fast growing global biotech company accelerating development of an innovative pipeline to treat unmet medical disease for patients worldwide.
Biosion is your partner of choice because:
- We empower partners by contributing an innovative pipeline of global competitiveness.
- We accelerate our partner’s clinical development through joint development efforts.
- We maximize the value of the collaboration through the synergy of an innovative Discovery platform, deep global development expertise and operational excellence.
Our world class discovery and development team has a track record of successfully delivering novel therapies for patients globally.
We are committed to advancing our internal pipeline as well as accessing external innovation to advance this goal.
A U.S.-based, Nasdaq listed company developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. www.celldex.com
China-based innovative pharmaceutical group that engages in drug R&D, manufacturing, and marketing. www.cttq.com
For more information and full pipeline details, please visit www.OBIPharma.com.
To learn more about Pyxis Oncology, visit www.pyxisoncology.com.
To learn more about Anke Biotechnology, visit https://www.ankebio.com/
Biosion is supported by prestigious investors
3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. https://www.3ebiovc.com/
Lapam Capital is a healthcare-focused venture capital firm targeting early stage and fast-growing opportunities.